Sanaria, Inc.

Rockville, MD 20850

SBIR Award Summary

Total Number of Awards 85
Total Value of Awards $57.4MM
First Award Date 07/01/03
Most Recent Award Date 08/02/17

Key Personnel

Last Name Name Awards Contact
Hoffman Stephen Lev Hoffman 70
Chakravarty Sumana Chakravarty 2
Billingsley Peter F. Billingsley 13

85 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 08/02/17 - 07/31/18

Abstract An ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmission. Sanaria has developed two effective vaccines that are phase 2 clinical trials; Pf sporozoite (SPZ) vaccine...

Phase SBIR

Agency: Department of Health & Human Services
Topic: PAR-16-027
Budget: 08/01/17 - 07/31/18

ABSTRACT Sanaria?s Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines development program is receiving overwhelming global support. Eleven trials of Sanaria?s two primary PfSPZ vaccines which include ~1,500 subjects, were initiated in late 2015 (Tanzania, U.S.) or will start in early 2016 (Kenya, Ghana, Equatorial Guinea (EG), Burkina Faso, Ge...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 06/20/17 - 05/31/18

ABSTRACT: The global death toll from Malaria is estimated to be upwards of 600,000 people each year, with more than 1,000 children succumbing every day. Plasmodium falciparum (Pf) Sporozoite (SPZ)-based vaccines are the only intervention in humans, proven to induce robust, high-level (>90%) and long-lasting (at least 14 months) protective effica...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 06/01/17 - 05/31/18

ABSTRACT Sanaria?s Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines development program is receiving global support. Trials of PfSPZ Vaccine (radiation attenuated PfSPZ) or PfSPZ-CVac (PfSPZ Chemoprophylaxis Vaccine) administered by direct venous inoculation (DVI), including ~1,500 adults to infants were initiated in December 2015 (Tanzania,...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 06/01/17 - 05/31/18

? DESCRIPTION (provided by applicant): The world needs a highly effective malaria vaccine. Sanaria(r) PfSPZ Vaccine, composed of aseptic, purified, cryopreserved radiation attenuated PfSPZ, protected 100% of volunteers in an NIH clinical trial. The vaccine has been administered by direct venous inoculation (DVI) to 371 subjects in Mali, Tanz...

Phase SBIR

Agency: Department of Health & Human Services
Topic: PAR-16-027
Budget: 05/01/17 - 04/30/18

ABSTRACT The development of Sanaria?s Plasmodium falciparum (Pf) sporozoite (SPZ)-based vaccines is receiving overwhelming global support after the publication in 2013 in Science of clinical data showing 100% protection against controlled human malaria infection (CHMI) following intravenous administration of 5 doses of Sanaria® PfSPZ Vaccine, co...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 04/01/17 - 03/31/18

? DESCRIPTION (provided by applicant): Plasmodium vivax (Pv), the second most important human malaria parasite, causes more than 80 million cases annually including severe, fatal disease. Prevention and control are challenged by emerging drug resistance and relapses from dormant liver stage parasites called hypnozoites. The only therapy again...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/17 - 12/31/17

? DESCRIPTION (provided by applicant): Sanaria's platform technology is production of aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ). This technology has produced three products administered by needle and syringe, all of which are in clinical trials - PfSPZ Vaccine (radiation attenuated PfSPZ), PfSPZ Challenge (...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/17 - 12/31/17

? DESCRIPTION (provided by applicant): We build on the successful work in Phase II SBIR 5R43AI069631-02 in which a genetically attenuated Plasmodium falciparum (Pf) parasite (GAP) was produced and shown to generate aseptic Pf sporozoites (SPZ) that invade hepatocytes, but do not replicate. We will use this genetically attenuated double-mutant...

Phase SBIR

Agency: Department of Health & Human Services
Topic: PAR-16-027
Budget: 08/01/16 - 07/31/17

Sanaria's Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines development program is receiving overwhelming global support. Eleven trials of Sanaria's two primary PfSPZ vaccines which include ~1,500 subjects, were initiated in late 2015 (Tanzania, U.S.) or will start in early 2016 (Kenya, Ghana, EquatorialGuinea (EG), Burkina Faso, Germany, and...

Load More